Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Neoplasias of the hepatopancreatobiliary tract are growing in numbers, have the poorest prognosis of all major cancer entities, and thus represent a rising clinical problem. Their molecular diagnostic has dramatically improved, contributing to tumor subtyping, definition of malignancy, and uncoverin...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February
|
| In: |
Virchows Archiv
Year: 2024, Volume: 484, Issue: 2, Pages: 263-272 |
| ISSN: | 1432-2307 |
| DOI: | 10.1007/s00428-024-03744-5 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00428-024-03744-5
|
| Author Notes: | T. Longerich, A. Stenzinger, P. Schirmacher |
| Summary: | Neoplasias of the hepatopancreatobiliary tract are growing in numbers, have the poorest prognosis of all major cancer entities, and thus represent a rising clinical problem. Their molecular diagnostic has dramatically improved, contributing to tumor subtyping, definition of malignancy, and uncovering cases with hereditary predisposition. Most of all, predictive molecular testing allows to identify cases amenable to treatment with the rising number of approved targeted drugs, immune-oncological treatment, and clinical trials. In this review, the current state of molecular testing and its contribution to clinical decision-making are outlined. |
|---|---|
| Item Description: | Online veröffentlicht am 1. März 2024 Gesehen am 25.06.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1432-2307 |
| DOI: | 10.1007/s00428-024-03744-5 |